Literature DB >> 9291425

Differential expression of the neuroendocrine genes Hel-N1 and HuD in small-cell lung carcinoma: evidence for down-regulation of HuD in the variant phenotype.

P H King1.   

Abstract

Hel-NI and HuD belong to the elav gene family and have gained recent attention as potential neuroendocrine markers for small-cell lung carcinoma (SCLC). Members of this conserved family normally appear at different stages of neuronal maturation, raising the possibility that their expression patterns in SCLC reflect the degree of neuroendocrine differentiation. I have utilized a ribonuclease protection assay to analyze Hel-NI and HuD expression in cultured SCLC cells with high (classic phenotype) and low (variant phenotype) levels of neuroendocrine differentiation. Hel-NI was detected in both classic and variant SCLC. Although HuD was detected consistently in classic SCLC, it was low to absent in variant SCLC, indicating a significant down-regulation in that phenotype. The expression patterns of Hel-NI and HuD also were analyzed in 9 primary SCLC and 10 non-SCLC lung-tumor samples. In the majority of SCLC samples, either Hel-NI or HuD was detected exclusively or predominantly, indicating a pattern of variable gene expression similar to cultured SC LC. Neither transcript could be detected in the non-SCLC samples. These data indicate that (i) HuD mRNA expression is associated with a higher level of neuroendocrine differentiation in SCLC, (ii) Hel-NI and HuD expressions are variable in both primary and cultured SCLC and (iii) HuD and Hel-NI, in combination, are neurogenetic markers for SCLC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291425     DOI: 10.1002/(sici)1097-0215(19970822)74:4<378::aid-ijc3>3.0.co;2-s

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies.

Authors:  Adriaan H C de Jongste; Marieke T de Graaf; Emanuela Martinuzzi; Patricia D M van den Broek; Jaco Kraan; Cor H J Lamers; Roberto Mallone; Jan W Gratama; Peter A E Sillevis Smitt
Journal:  Neuro Oncol       Date:  2012-05-15       Impact factor: 12.300

Review 2.  Post-transcriptional regulatory elements and spatiotemporal specification of neocortical stem cells and projection neurons.

Authors:  E M DeBoer; M L Kraushar; R P Hart; M-R Rasin
Journal:  Neuroscience       Date:  2013-05-30       Impact factor: 3.590

Review 3.  Roles of Embryonic Lethal Abnormal Vision-Like RNA Binding Proteins in Cancer and Beyond.

Authors:  Haijian Cai; Dandan Zheng; Yizhu Yao; Lehe Yang; Xiaoying Huang; Liangxing Wang
Journal:  Front Cell Dev Biol       Date:  2022-04-06

4.  Immune response in lung cancer mouse model mimics human anti-Hu reactivity.

Authors:  Meleeneh Kazarian; Joaquim Calbo; Natalie Proost; Catherine L Carpenter; Anton Berns; Ite A Laird-Offringa
Journal:  J Neuroimmunol       Date:  2009-09-17       Impact factor: 3.478

Review 5.  RNA-Binding Protein HuD as a Versatile Factor in Neuronal and Non-Neuronal Systems.

Authors:  Myeongwoo Jung; Eun Kyung Lee
Journal:  Biology (Basel)       Date:  2021-04-23

6.  CDR2 antigen and Yo antibodies.

Authors:  Cecilie Totland; Nina K Aarskog; Tilo W Eichler; Mette Haugen; Jane K Nøstbakken; Sissel E Monstad; Helga B Salvesen; Sverre Mørk; Bjørn I Haukanes; Christian A Vedeler
Journal:  Cancer Immunol Immunother       Date:  2010-11-16       Impact factor: 6.968

Review 7.  Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis.

Authors:  Jun Wang; Yan Guo; Huili Chu; Yaping Guan; Jingwang Bi; Baocheng Wang
Journal:  Int J Mol Sci       Date:  2013-05-10       Impact factor: 5.923

8.  No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies.

Authors:  Janet W de Beukelaar; Georges M Verjans; Yvette van Norden; Johannes C Milikan; Jaco Kraan; Herbert Hooijkaas; Kees Sintnicolaas; Jan W Gratama; Peter A Sillevis Smitt
Journal:  Cancer Immunol Immunother       Date:  2007-02-14       Impact factor: 6.968

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.